NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Caribou Biosciences, Inc. CRBU
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$11.2M
▲ 11.7% vs FY2024
EPS · FY25
$-1.59
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-79.0%
Net margin · FY25
-1327.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 11.2M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 1327 cents on every revenue dollar this year.
Per share
USD -1.59
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-79.0%
Return on equity, FY2025
ROE
Operating margin-1329.4%
Net margin-1327.4%
Return on assets-60.6%
Each USD of equity lost 79 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−2.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−7.0%
−2.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 175.4M
total assets, end of FY2025
Total assetsUSD 175.4M
EquityUSD 122.2M
CashUSD 12.4M
Current ratio5.71×
Equity funds 70% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.1
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
Income tax $B
−0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−1.59
−1.65
−1.38
−1.64
−2.11
−4.01
−2.80
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−79.0
−48.0
−30.5
−28.9
−36.7
·
−314.0
Shares out B
0.10
0.09
0.09
0.06
0.06
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
19 of 19
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed